Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy and tolerability of alitretinoin in treating severe chronic hand eczema

Three trials were conducted to evaluate the efficacy and safety of oral alitretinoin (10 or 30 mg/day) in the treatment of severe chronic hand eczema (CHE). Trial A was a double-blind, randomized, placebo-controlled study in 1,032 patients using 10 or 30 mg/day alitretinoin or placebo for 24 weeks. Trial B was an open-label, fixed dose (alitretinoin 30 mg/day) in 249 patients for 24 weeks. Trial C was a double-blind, placebo-controlled study of 117 patients who responded in study A and relapsed within 24 weeks. Patients were rerandomized to a second dose of alitretinoin or placebo. In trial A, a "clear" or "almost clear" response on the Physician's Global Assessment was significantly greater ...